T. Rowe Price Investment Management, Inc. Zentalis Pharmaceuticals, Inc. Transaction History

T. Rowe Price Investment Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.09 - $16.13 $8.15 Million - $32.2 Million	-1,993,595 Reduced 60.06%	1,325,491 $5.42 Million
Q1 2024 May 15, 2024	BUY	$10.83 - $16.49 $10.6 Million - $16.1 Million	977,303 Added 41.73%	3,319,086 $52.3 Million
Q4 2023 Feb 14, 2024	BUY	$9.84 - $20.13 $3.63 Million - $7.43 Million	369,299 Added 18.72%	2,341,783 $35.5 Million
Q3 2023 Nov 14, 2023	SELL	$19.63 - $28.29 $527,458 - $760,152	-26,870 Reduced 1.34%	1,972,484 $39.6 Million
Q2 2023 Aug 14, 2023	SELL	$17.41 - $30.05 $192,467 - $332,202	-11,055 Reduced 0.55%	1,999,354 $56.4 Million
Q1 2023 May 15, 2023	SELL	$16.14 - $24.94 $3.23 Million - $4.99 Million	-200,033 Reduced 9.05%	2,010,409 $34.6 Million
Q4 2022 Feb 14, 2023	BUY	$18.07 - $25.6 $32,038 - $45,388	1,773 Added 0.08%	2,210,442 $44.5 Million
Q3 2022 Nov 14, 2022	BUY	$20.23 - $31.73 $44.7 Million - $70.1 Million	2,208,669 New	2,208,669 $47.8 Million

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of T. Rowe Price Investment Management, Inc., based on Form 13F filings with the SEC.

Stay updated on T. Rowe Price Investment Management, Inc. with notifications on news.